Colinz Labs declares non-applicability of related party disclosures

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • Colinz Laboratories Limited declared non-applicability of Related Party Transaction disclosures for Q2FY27
  • Company cited exemption under Regulation 15(2)(a) of SEBI (LODR) Regulations, 2015
  • Compliance with Regulations 17 to 27 and specific clauses of Regulation 46 is not applicable
  • Filing signed by Director Vijaya Mani on October 1, 2026
powered bylight_fuzz_icon
52390678

*this image is generated using AI for illustrative purposes only.

Colinz Laboratories Limited has informed the Bombay Stock Exchange that it is not required to submit Related Party Transaction (RPT) disclosures for the quarter ended September 30, 2026. The company invoked an exemption under SEBI regulations to bypass this specific compliance requirement.

The declaration was made pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company stated that compliance with provisions specified in Regulations 17 to 27 and clauses (b) to (i) [and (t)] of sub-regulation (2) of Regulation 46, along with para C, D, and E of Schedule V, shall not apply.

Regulatory Basis for Exemption

The company claimed exemption under Regulation 15(2)(a) of the SEBI (LODR) Regulations, 2015. This regulation allows certain entities to be exempt from specific governance and disclosure norms if they meet defined criteria, such as being a subsidiary or having a specific shareholder structure. Consequently, the mandatory submission of RPT details for the second quarter of fiscal year 2027 is waived.

Key Filing Details

Detail Information
Quarter Ended September 30, 2026
Regulation Cited Regulation 23(9), SEBI LODR
Exemption Clause Regulation 15(2)(a), SEBI LODR
Signatory Vijaya Mani, Director

The filing was digitally signed by Vijaya Mani, Director of the company, on October 1, 2026. The communication was addressed to the BSE at Phiroze Jeejeebhoy Towers, Mumbai. No financial performance metrics or operational updates were disclosed in this specific regulatory filing.

Historical Stock Returns for Colinz Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-4.16%-0.54%-0.68%+65.17%+77.97%+276.92%

How might the reliance on Regulation 15(2)(a) exemptions impact investor confidence in Colinz Laboratories' corporate governance transparency compared to peers?

Will SEBI introduce stricter scrutiny or regulatory changes targeting companies that frequently utilize governance exemptions to bypass RPT disclosures?

What specific shareholder structure criteria is Colinz Laboratories leveraging to maintain its eligibility for the Regulation 15(2)(a) exemption in future quarters?

Colinz Labs shareholders approve all resolutions at 40th AGM

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • All four resolutions at the 40th AGM passed with requisite majority
  • Promoters voted in favour of all leadership reappointments
  • Only 6 votes against recorded across all resolutions
  • No physical attendance; all participation via VC/OAVM
powered bylight_fuzz_icon
51626877

*this image is generated using AI for illustrative purposes only.

Colinz Laboratories Limited shareholders have approved all resolutions proposed at the company's 40th Annual General Meeting, held on September 22, 2026. The voting results, disclosed on September 23, 2026, confirm the adoption of FY26 financial statements and key governance changes.

The meeting was conducted via Video Conferencing or Other Audio Video Means (OAVM). Mrs. Vijaya Mani served as Chairperson. She confirmed the presence of a quorum and acknowledged the sad demise of Late Dr. Mani L.S., the Founder Director and Promoter, during the financial year.

Key resolutions approved

The Board commended several items of business for member approval, covering both ordinary and special business. The audited financial statements for the year ended March 31, 2026, along with the reports of the Board of Directors and Auditors, were adopted.

Resolution Type Details
Adoption of Financial Statements Ordinary For the year ended March 31, 2026
Reappointment of Director Ordinary Mr. N. K. Menon (DIN-01111297) retiring by rotation
Appointment of Director Ordinary Mrs. Vijaya Mani (DIN: 11363910) as Non-Executive Non-Independent Director
Reappointment of CEO Special Mr. N. K. Menon as Whole Time Director & Chief Executive Officer

Governance updates

Mr. N. K. Menon, who serves as the Whole Time Director and Chief Executive Officer, was reappointed following his retirement by rotation. Additionally, members approved his continued remuneration package through a special resolution. Mrs. Vijaya Mani was formally appointed as a Director in her capacity as a Non-Executive Non-Independent Director.

Voting results and attendance

The scrutinizer's report dated September 23, 2026, detailed the voting outcomes. A total of 32 shareholders participated in the voting process, combining remote e-voting and electronic voting during the meeting. Notably, no shareholders attended the meeting in person or through proxy.

Attendance via Video Conferencing included 14 promoters/promoter group members and 18 public shareholders. The total number of shareholders on record was 3,195.

Resolution-wise voting summary

Resolution Votes in Favour Votes Against Result
Adoption of Financial Statements 12,61,269 6 Passed
Reappointment of Director (N.K. Menon) 12,61,169 6 Passed
Appointment of Director (Vijaya Mani) 3,90,769 6 Passed
Reappointment of CEO (N.K. Menon) 12,61,169 6 Passed

The promoters and promoter group held 12,74,659 shares and cast votes on 8,70,500 shares for most resolutions, voting entirely in favour. Public non-institutional shareholders voted on approximately 3,90,675 shares, with only 6 votes cast against across all resolutions.

The meeting concluded at 3:03 pm after the Chairperson informed members that the results of the e-voting would be reconciled by the Scrutinizer, M/s. Ashwini Vaze & Associates. The final report is now available on the company website and relevant stock exchange platforms.

Historical Stock Returns for Colinz Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-4.16%-0.54%-0.68%+65.17%+77.97%+276.92%

How will the formal appointment of Mrs. Vijaya Mani as a Non-Executive Non-Independent Director influence Colinz Laboratories' strategic direction following the passing of founder Dr. Mani L.S.?

What are the implications of the extremely low shareholder participation (less than 1% of registered holders) for the company's future corporate governance credibility and market perception?

Will the reappointment of CEO N.K. Menon with an approved remuneration package signal a continuation of existing operational strategies or indicate a shift in management priorities for FY27?

More News on Colinz Laboratories

1 Year Returns:+77.97%